Health & Fitness
Health and Fitness
Health and Fitness
Wed, February 4, 2009 Compugen Ltd. to Review Fourth Quarter and Year-End 2008 Financial Results on Wednesday, February 11, 2009
TEL AVIV, Israel--([ BUSINESS WIRE ])--Compugen Ltd. (NASDAQ: CGEN) today announced that the Company plans to host a live conference call and webcast at 10:00 AM EST on Wednesday, February 11, 2009 to review fourth quarter and year-end 2008 results. The quarterly and year-end results will be released prior to the conference call.
To access the conference call, please dial 180-921-4368 from Israel, 1-866-691-3082 from the US or 1-480-629-1941 internationally. After dialing in, you will be asked which conference you are joining. Please state either Compugen or 3969859. The call will also be available via live webcast through Compugen's Website, located at [ www.cgen.com ].
A replay of the conference call will be available from February 11, 2009 at 1:00 pm EST through February 13, 2009 at 1:00 pm EST. To access the replay, please dial 077-300-6288 from Israel, toll free 1-800-406-7325 from the US or 1-303-590-3030 internationally. The replay code is 3969859#.
About Compugen
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in-silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. The resulting product candidates are then validated through in vitro and in vivo experimental studies and out-licensed for further development and commercialization under various forms of revenue sharing agreements. Compugen's current collaborations include Biosite; Medarex, Inc.; Merck & Co., Inc.; Ortho-Clinical Diagnostics (a Johnson & Johnson company); Roche; Siemens Healthcare Diagnostics, Inc.; and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate, Evogene Ltd. [ www.evogene.com ] (TASE: EVGN.TA), to utilize certain of the Company's in-silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate Web site at [ www.cgen.com ].
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's annual reports filed with the Securities and Exchange Commission.
